HCPLive Network

Glucagonlike Peptide 1 Therapies Increase Pancreatitis Risk

THURSDAY, Feb. 28 (HealthDay News) -- Use of glucagonlike peptide 1 (GLP-1)-based therapies (GLP-1 mimetic, exenatide, and dipeptidyl peptidase 4 inhibitor, sitagliptin phosphate) correlates with increased likelihood of hospitalization for acute pancreatitis among adults with type 2 diabetes, according to a study published online Feb. 25 in JAMA Internal Medicine.

Sonal Singh, MD, MPH, from Johns Hopkins University School of Medicine, in Baltimore, and colleagues conducted a population-based study using data from a large U.S. administrative database (Feb. 1, 2005 through Dec. 31, 2008). Using a validated algorithm, they identified 1,269 adults with type 2 diabetes, hospitalized with acute pancreatitis, who were matched for age, sex, and diabetes complications with 1,269 control subjects.

The researchers found that cases were significantly more likely to have hypertriglyceridemia, alcohol use, gallstones, tobacco abuse, obesity, biliary and pancreatic cancer, cystic fibrosis, and any neoplasm, compared with controls. Relative to nonusers, the odds of acute pancreatitis were significantly increased for those with current use of GLP-1-based therapies within 30 days (adjusted odds ratio, 2.24) and recent use past 30 days and less than two years (adjusted odds ratio, 2.01), after adjustment for other confounding variables including metformin hydrochloride use.

"In this administrative database study of U.S. adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with increased odds of hospitalization for acute pancreatitis," write the authors.

The original development of the dataset used in this study was funded by grants from the pharmaceutical and medical device industries.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Treatment failure can be caused by a variety of factors, including misdiagnosis of the primary psychiatric complaint, the presence of one or more comorbid conditions, and nonadherence to medication plans.
When treating patients who have been diagnosed with cancer, you should consult with their oncologist to brainstorm interventions that can help your patient have the best possible quality of life.
Prolonged exposure therapy can help veterans with post-traumatic stress disorder overcome the fear, anxiety, and depression that can lead to avoidance behaviors and other responses that negatively impact quality of life.
App will help patients with diabetes log their hypoglycemic events and achieve better control of these events by becoming more aware of preceding signs and symptoms.
Provocative research raises the question of whether we should we look at Alzheimer’s disease as “type 3 diabetes.”
Presentation at CMHC 2014 provides updates on emerging classes of diabetes treatment, including preliminary data from current clinical trials.
In remarks delivered at the American Academy of Family Physicians 2014 Assembly, HHS Secretary Sylvia Mathews Burwell spoke about the ongoing response to the Ebola outbreak, improving health care delivery, the Affordable Care Act, and the Transforming Clinical Practice Initiative.
More Reading